The Pharmaceutical Journal
Vol 271 No 7259 p115
26 July 2003

This article
Reprint
Photocopy

Products

Prescription Products
• Torasemide
SPC changes
• Botox SPC update
• COPD indication for Seretide
Discontinued products
• Dermestril patch

Prescription Products

Torasemide

PLIVA Pharma has launched torasemide tablets; net price, 5mg 28 £5.94, 10mg 28 £8.74.

Back to Top

SPC changes

Botox SPC update

The summary of product characteristics for Botox (botulinum toxin type A) has been updated (Allergan). It is now contraindicated in patients with Eaton Lambert syndrome. The warning about interaction with anticoagulants has been removed and a number of general warnings have been added (eg, rare anaphylactic reactions, caution with dysphagia, possibility of resistance to treatment). Other sections of the SPC, including undesirable effects, have also been updated. See SPC.

COPD indication for Seretide

The summary of product characteristics for Seretide (fluticasone propionate plus salmeterol xinafoate) has been updated (GlaxoSmithKline). Seretide is now additionally licensed for the treatment of patients with severe chronic obstructive pulmonary disease (FEV1 <50 per cent predicted normal) and a history of repeated exacerbations despite regular bronchodilator therapy. The recommended adult dose is one inhalation of 50µg salmeterol and 500µg fluticasone propionate twice daily.

Back to Top

Discontinued products

Dermestril patch

Strakan Ltd will no longer be supplying Dermestril 50 transdermal patch (releasing approximately 50mg estradiol in 24 hours) in the United Kingdom from 1 August. Further information from the company on 01896 668066.

Back to Top